eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2015-02-15 2 1 13 16 546 article Nadeem Siddiqui 1 M. Shamsher Alam 1 Sharique Ahmed 2 Ruhi Ali 1 M. Faiz Arshad 1 Waquar Ahsan 1 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Hamdard University, Hamdard Nagar, New Delhi - 110 062 (India). Department Biochemistry, Faculty of Medicine, 7th October University, Misurata (India). Sepracor Inc. (Nasdaq: SEPR) announced the presentation of Phase III combined clinical results for eslicarbazepine acetate (SEP-0002093 / BIA 2-093) in the treatment of epilepsy at the Ninth Eilat Conference on New Anti-Epileptic Drugs in Spain. The study demonstrates that eslicarbazepine is well tolerated and effective when used as adjunct therapy for adult patients with partial epilepsy with distinctively lesser side effects. The pharmacological and computational properties of eslicarbazepine have been studied and discussed. https://biomedpharmajournal.org/vol2no1/pharmacological-and-computational-approach-to-eslicarbazepine-a-short-review/ Eslicarbazepine Pharmacokinetics Antiepileptic Computational